Janus Henderson Group PLC Purchases 520,201 Shares of Amylyx Pharmaceuticals, Inc. $AMLX

Janus Henderson Group PLC increased its position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 11.6% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 4,986,073 shares of the company’s stock after acquiring an additional 520,201 shares during the quarter. Janus Henderson Group PLC’s holdings in Amylyx Pharmaceuticals were worth $69,257,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Landscape Capital Management L.L.C. lifted its holdings in Amylyx Pharmaceuticals by 17.5% during the fourth quarter. Landscape Capital Management L.L.C. now owns 12,226 shares of the company’s stock valued at $148,000 after purchasing an additional 1,825 shares during the last quarter. KBC Group NV bought a new position in Amylyx Pharmaceuticals during the first quarter worth about $26,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Amylyx Pharmaceuticals by 54.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,337 shares of the company’s stock worth $64,000 after purchasing an additional 1,890 shares in the last quarter. Meeder Asset Management Inc. purchased a new position in shares of Amylyx Pharmaceuticals in the fourth quarter worth about $25,000. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Amylyx Pharmaceuticals by 14.5% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 17,895 shares of the company’s stock valued at $216,000 after purchasing an additional 2,265 shares during the period. 95.84% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently commented on AMLX shares. Weiss Ratings restated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research note on Friday, May 8th. Wall Street Zen cut shares of Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. HC Wainwright reissued a “buy” rating and set a $34.00 target price on shares of Amylyx Pharmaceuticals in a report on Monday, June 8th. Mizuho increased their target price on Amylyx Pharmaceuticals from $21.00 to $24.00 and gave the stock an “outperform” rating in a research report on Monday, July 20th. Finally, Guggenheim raised their price target on Amylyx Pharmaceuticals from $30.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, June 25th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $24.62.

Amylyx Pharmaceuticals Stock Down 2.1%

Shares of AMLX opened at $20.31 on Friday. The business’s 50-day moving average price is $16.55 and its 200-day moving average price is $15.45. Amylyx Pharmaceuticals, Inc. has a twelve month low of $7.48 and a twelve month high of $20.94. The stock has a market cap of $2.26 billion, a PE ratio of -13.54 and a beta of -0.20.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). Analysts expect that Amylyx Pharmaceuticals, Inc. will post -1.4 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Gina Mazzariello sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $18.32, for a total transaction of $274,800.00. Following the sale, the insider owned 194,090 shares of the company’s stock, valued at approximately $3,555,728.80. This represents a 7.17% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 10.90% of the company’s stock.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.